Background: PROs of NASH patients have not been fully assessed. We assessed the impact of fatigue and pruritus on PROs of patients with advanced NASH.

Methods: Baseline PROs including fatigue and pruritis (SF-36, CLDQ-NASH, EQ-5D, and WPAI instruments) were collected from patients with biopsy-proven NASH and advanced fibrosis (stage≥F3).

Results: Fatigue (33%) and pruritus (27%) were reported among NASH patients (n=1,669; mean age 58±9 years, 48% F3, 42% psychiatric comorbidities). Fatigued patients were younger, female, cirrhotic, diabetic with higher BMI and more comorbidities (all p<0.05) than those without fatigue. Fatigued patients also had lower albumin, higher alkaline phosphatase (ALP), bile acids, glucose, HbA1c, C-reactive protein (CRP), GGT, ELF, Fibrotest, NFS, and liver stiffness (p<0.05). PROs of fatigued patients were significantly impaired (mean up to -31.4% of a PRO range). In multivariate analysis, predictors of fatigue were female gender [OR=1.47 (1.15-1.89)], history of depression [2.18 (1.67-2.83)], lower serum albumin, younger age, non-Asian race, diabetes, other nervous system or psychiatric comorbidities and some laboratory tests (p<0.05). NASH patients with pruritus had similar demographic profile to fatigued patients but had more skin-related comorbidities than patients without pruritus and a lower hemoglobin and serum albumin, higher ALP, fasting glucose, HOMA, HbA1c, CRP, GGT, higher liver stiffness, ELF, and NFS (all p<0.05). Pruritus patients had impairment in all PROs (all p<0.01). Female gender [odds ratio (OR)=1.33 [1.05-1.68)], history of depression (1.53 (1.19-1.96), nervous [1.40 (1.11-1.77)] and skin-related [1.59 (1.25-2.01)] comorbidities and lower serum albumin were associated with a greater risk of pruritus (p<0.05).

Conclusion: One-third of patients with advanced NASH have fatigue and pruritus which negatively impact their PROs.


Z. Younossi: Consultant; Self; AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novo Nordisk Inc., Terns and Viking. Q. Anstee: Consultant; Self; 89Bio, Abbott Laboratories, Acuitas Medical, Allergan/Tobira, AstraZeneca, Axcella, Blade, BNN Cardio, Celgene, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit S, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Madrigal, MedImmune, Metacrine, NewGene, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, Pfizer Ltd., Poxel, ProSciento, Raptor Pha. Research Support; Self; Abbvie, Allergan/Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd., Vertex. Speaker’s Bureau; Self; Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, MedScape. V.W.S. Wong: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Gilead Sciences, Inc. Consultant; Self; AbbVie Inc., Allergan plc., Echosens, Intercept Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Pfizer Inc. M. Trauner: Advisory Panel; Self; Gilead Sciences, Inc. Research Support; Self; Gilead Sciences, Inc. Speaker’s Bureau; Self; Gilead Sciences, Inc. Other Relationship; Self; Gilead Sciences, Inc. M. Camargo: Employee; Self; Gilead Sciences, Inc. Z. Goodman: None. L. Henry: None. M. Stepanova: None. M. Romero-Gomez: Consultant; Self; Kaleido Biosciences, Merck & Co., Inc., Novo Nordisk Inc., Siemens Corporation, Zydus Pharmaceuticals, Inc. R. Myers: None. E. Lawitz: None.


Gilead Sciences Foundation

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at